Replies to post #345431 on Elite Pharmaceuticals Inc (ELTP)

[no2koolaid]

Not sure where the 10 cents came from, it's not in any of my calculations. Here is what I wrote...

If we use a projected peak revenue for their current IR & XR CNS generics of $180M and a 4.5x peak revenues, that gives Elite a valuation of $810M or about 80 cents a share. This before considering the still to be developed but much hoped for CNS drug with a $1.5 B market. With a consistent market capture, that puts Elite at about $300M in annual revenues. So, with a 4.5x revenue projection, Elite would be worth about $1.35 p/s.

Also, as I noted...

In pharma, we have seen - roughly - a 4.5x multiple for projected peak revenues.

OBTW: Many thanks to all who continue to offer kind observations. Just trying to get beyond the nonsense and discuss business from a pragmatic perspective.